Highmark Interactive Inc. Announces Update to Cease Trade Order and Reimbursement of Remote Patient Monitoring Services
“We are excited to offer our clients the ability to bill for remote patient monitoring services,” said Dr.
In regards to an update of the Cease
About
In addition to a growing network of virtual, in-person and hybrid clinics.
Neither
Learn more: https://www.highmark.tech/
For further information:
[email protected] or 1-855-969-5079 Investor Relations
SOURCE:
Cautionary Note Regarding Forward-Looking Information
This News Release contains forward-looking statements that relate to the current expectations and views of future events of the Company. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”,
or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, predictions, indications, projections or other characterizations of future events or circumstances contain forward-looking information.
Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events. Forward-looking statements in this news release include, among other things, statements and expectations relating to the validation of the Company’s technology and the continued reimbursement by Medicare for remote patient monitoring services, remedying defaults with respect to filing of the 2022 annual consolidated financial statements and the timing therefore, potential avenues for additional external financing, and the nature of discussions with secured creditors and the outcomes of such discussions.
These statements and other forward-looking information are based on opinions, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that Highmark believes are appropriate and reasonable in the circumstances as of the date of this news release, including discussions with potential financing parties and secured creditors.
There can be no assurance that such estimates and assumptions will prove to be correct. In addition, if any of the assumptions or estimates made by management prove to be incorrect, actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking information contained herein. Accordingly, prospective investors are cautioned not to place undue reliance on such information. Although the Company believes the assumptions underlying the statements related to the Company are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, and the risks identified in the filing statement, investors should not place undue reliance on these forward-looking statements.
Source:
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mass General Brigham: New Framework for Defining Long COVID Highlights 12 Signature Symptoms
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News